

Haematologica
HAEMATOL/2018/203729
Version 4

Mathematical modeling reveals alternative JAK inhibitor treatment in
myeloproliferative neoplasms

Kaitlyn Shank, Andrew Dunbar, Priya Koppikar, Maria Kleppe, Julie Teruya-Feldstein, Isabelle Csete, Neha Bhagwat, Matthew Keller, Outi Kilpivaara, Franziska Michor, Ross L. Levine, and Laura de Vargas Roditi

Disclosures: R.L.L. is on the supervisory board of Qiagen and is a scientific advisor to Loxo, Imago, C4 Therapeutics and Isoplexis, which each include an equity interest. He receives research support from and consulted for Celgene and Roche, he has received research support from Prelude Therapeutics, and he has consulted for Incyte, Novartis, Morphosys and Janssen. He has received honoraria from Lilly and Amgen for invited lectures and from Gilead for grant reviews. This work was supported by NCI P01 CA108671 and NCI R35197594 to R.L.L., by the Janus Project to R.L.L., and by a LLS SCOR grant to R.L.L. Studies supported by MSK core facilities were supported in part by MSKCC Support Grant/Core Grant P30 CA008748.

Contributions: In regards to author contribution, K.S., F.M., R.L.L. and L.D.V.R. conceived the study. K.S. and L.D.V.R. performed all experiments with help from A.D., P.K., N.B., M.K., I.C., and O.K.. L.D.V.R. and K.S. performed the in vitro experiments with help from O.K. while K.S. performed the in vivo experiments with help from A.D., P.K. N.B., M.K. and I.C.. The analysis of pathology slides was performed by J.T.. L.D.V.R. developed the mathematical model and performed computational simulations. K.S., F.M., R.L.L. and L.D.V.R. wrote the manuscript. All authors provided feedback on the manuscript.